RSRC2

Summary

RSRC2 (arginine and serine rich coiled-coil 2, HGNC:30559) is a protein-coding gene on chromosome 12q24.31, encoding Arginine/serine-rich coiled-coil protein 2 (Q7L4I2). It is a selective cancer dependency (DepMap: 38.4% of cell lines).

Enables RNA binding activity.

Source: NCBI Gene 65117 — RefSeq curated summary.

At a glance

• Gene–disease (curated): complex neurodevelopmental disorder (Limited, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 58 total — 1 likely-pathogenic
• Phenotypes (HPO): 2
• Cancer dependency (DepMap): dependent in 38.4% of screened cell lines
• MANE Select transcript: NM_023012

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30559
Approved symbol	RSRC2
Name	arginine and serine rich coiled-coil 2
Location	12q24.31
Locus type	gene with protein product
Status	Approved
Aliases	FLJ11021
Ensembl gene	ENSG00000111011
Ensembl biotype	protein_coding
OMIM	619996
Entrez	65117

Gene structure

Transcript identifiers

Ensembl transcripts: 25 — 9 protein_coding, 8 retained_intron, 4 protein_coding_CDS_not_defined, 4 nonsense_mediated_decay

ENST00000331738, ENST00000344591, ENST00000392442, ENST00000433877, ENST00000524399, ENST00000525332, ENST00000525335, ENST00000525387, ENST00000525570, ENST00000526560, ENST00000527173, ENST00000527399, ENST00000527461, ENST00000527796, ENST00000528263, ENST00000528279, ENST00000531389, ENST00000531639, ENST00000532186, ENST00000532695, ENST00000868444, ENST00000868445, ENST00000868446, ENST00000868447, ENST00000868448

RefSeq mRNA: 1 — MANE Select: NM_023012 NM_023012

CCDS: CCDS31920

Canonical transcript exons

ENST00000331738 — 10 exons

Exon	Start	End
ENSE00002204725	122503454	122505706
ENSE00002209590	122526848	122526936
ENSE00003467794	122511109	122511188
ENSE00003526616	122522143	122522299
ENSE00003554697	122508218	122508447
ENSE00003566004	122521385	122521428
ENSE00003615721	122515105	122515227
ENSE00003625848	122506834	122506923
ENSE00003645836	122518839	122519029
ENSE00003668353	122517227	122517430

Expression profiles

Bgee: expression breadth ubiquitous, 295 present calls, max score 99.08.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 86.2401 / max 2225.2403, expressed in 1825 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
133835	77.9178	1824
133836	4.2634	1455
133831	1.8175	731
133829	0.8849	460
133834	0.5683	145
133830	0.5199	200
133832	0.1411	41
133833	0.1272	44

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	99.08	gold quality
calcaneal tendon	UBERON:0003701	98.94	gold quality
ventricular zone	UBERON:0003053	98.82	gold quality
ganglionic eminence	UBERON:0004023	98.50	gold quality
mucosa of stomach	UBERON:0001199	97.95	gold quality
tendon	UBERON:0000043	97.78	gold quality
embryo	UBERON:0000922	97.78	gold quality
colonic epithelium	UBERON:0000397	97.66	gold quality
cortical plate	UBERON:0005343	97.59	gold quality
sperm	CL:0000019	97.46	gold quality
right lung	UBERON:0002167	97.45	gold quality
left ovary	UBERON:0002119	97.41	gold quality
skin of hip	UBERON:0001554	97.31	gold quality
tibial nerve	UBERON:0001323	97.30	gold quality
bone marrow	UBERON:0002371	97.24	gold quality
right ovary	UBERON:0002118	97.23	gold quality
body of uterus	UBERON:0009853	97.21	gold quality
skin of abdomen	UBERON:0001416	97.17	gold quality
left lobe of thyroid gland	UBERON:0001120	97.14	gold quality
male germ cell	CL:0000015	97.13	gold quality
popliteal artery	UBERON:0002250	97.04	gold quality
small intestine Peyer’s patch	UBERON:0003454	97.04	gold quality
tibial artery	UBERON:0007610	97.04	gold quality
rectum	UBERON:0001052	97.03	gold quality
endocervix	UBERON:0000458	97.02	gold quality
right lobe of thyroid gland	UBERON:0001119	97.02	gold quality
thyroid gland	UBERON:0002046	97.02	gold quality
ectocervix	UBERON:0012249	97.02	gold quality
minor salivary gland	UBERON:0001830	96.98	gold quality
right uterine tube	UBERON:0001302	96.95	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-HCAD-31	yes	2878.93
E-MTAB-8495	yes	2613.74
E-CURD-89	no	832.00
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): SRSF1, SRSF2

miRNA regulators (miRDB)

62 targeting RSRC2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-576-5P	99.84	70.46	2582
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-3913-3P	99.74	66.53	938
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-7154-5P	99.69	70.52	1900
HSA-MIR-5700	99.64	69.88	2280
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-548AV-5P	99.60	70.84	2107
HSA-MIR-548K	99.60	70.84	2107
HSA-MIR-510-3P	99.54	70.06	2965
HSA-MIR-105-5P	99.54	69.24	2060
HSA-MIR-7853-5P	99.54	69.30	2055
HSA-MIR-143-3P	99.49	69.05	1457

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 38.4% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 2)

• RSRC2 might play a role in cell proliferation and progression of esophageal cancer (PMID:17203224)
• our findings suggest that paclitaxel targets the TRA2A-RSRC2 splicing pathway, and deregulated TRA2A and RSRC2 expression may confer paclitaxel resistance. In addition, our study demonstrates that expression of TRA2A in conjunction with RSRC2 may provide valuable molecular biomarker evidence for triple-negative breast cancer (TNBC)clinical treatment decisions and patient outcome (PMID:28416606)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	rsrc2	ENSDARG00000042534
mus_musculus	Rsrc2	ENSMUSG00000029422
rattus_norvegicus	Rsrc2	ENSRNOG00000001238

Paralogs (8): SRSF5 (ENSG00000100650), SRSF9 (ENSG00000111786), SRSF3 (ENSG00000112081), SRSF7 (ENSG00000115875), SRSF4 (ENSG00000116350), RSRP1 (ENSG00000117616), SRSF6 (ENSG00000124193), SRSF1 (ENSG00000136450)

Protein

Protein identifiers

Arginine/serine-rich coiled-coil protein 2 — Q7L4I2 (reviewed: Q7L4I2)

All UniProt accessions (6): Q7L4I2, E1B6W4, E9PI52, F5GYD2, F5H1Z2, H0YGP9

UniProt curated annotations — full annotation on UniProt →

Similarity. Belongs to the RSRC2 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q7L4I2-1	1	yes
Q7L4I2-2	2

RefSeq proteins (1): NP_075388* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR028124	SMAP_dom	Domain

Pfam: PF15477

UniProt features (22 total): modified residue 9, compositionally biased region 4, cross-link 2, initiator methionine 1, chain 1, splice variant 1, region of interest 1, sequence variant 1, sequence conflict 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7L4I2-F1	55.71	0.02

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (11): 6, 16, 17, 30, 32, 104, 376, 375, 375, 2, 4

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 151 (showing top): E2F_Q4_01, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GGGTGGRR_PAX4_03, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, GTGCCTT_MIR506, LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_DN, ICHIBA_GRAFT_VERSUS_HOST_DISEASE_35D_DN, DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_UP, AACTTT_UNKNOWN, NOUZOVA_TRETINOIN_AND_H4_ACETYLATION, MARTINEZ_RESPONSE_TO_TRABECTEDIN_DN, GNF2_DDX5, TGCCTTA_MIR124A, GCCATNTTG_YY1_Q6, CHEN_HOXA5_TARGETS_9HR_UP

GO Biological Process (0):

GO Molecular Function (2): RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nucleic acid binding	1
binding	1

Protein interactions and networks

STRING

1208 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RSRC2	KNTC1	P50748	676
RSRC2	TRA2A	Q13595	541
RSRC2	RSRC1	Q96IZ7	533
RSRC2	FIZ1	Q96SL8	518
RSRC2	MIER2	Q8N344	497
RSRC2	RCOR3	Q9P2K3	460
RSRC2	TMEM186	Q96B77	455
RSRC2	PRKCSH	P14314	425
RSRC2	ZMAT5	Q9UDW3	420
RSRC2	ZMYND19	Q96E35	411
RSRC2	PSMB5	P28074	406
RSRC2	ILRUN	Q9H6K1	401
RSRC2	FAM76B	Q5HYJ3	400
RSRC2	ZNF277	Q9NRM2	391
RSRC2	TMEM258	P61165	382

IntAct

204 interactions, top by confidence:

A	B	Type	Score
MED4	MED19	psi-mi:“MI:0914”(association)	0.900
MED20	MED19	psi-mi:“MI:0914”(association)	0.840
RSRC2	SRPK2	psi-mi:“MI:0217”(phosphorylation reaction)	0.690
FOXK2	DVL2	psi-mi:“MI:0914”(association)	0.640
P4HA3	FAM171A2	psi-mi:“MI:0914”(association)	0.640
RSRC2	APBA1	psi-mi:“MI:0407”(direct interaction)	0.590
CTAG1A	RSRC2	psi-mi:“MI:0915”(physical association)	0.560
RSRC2	CMTM5	psi-mi:“MI:0915”(physical association)	0.560
RSRC2	UBQLN2	psi-mi:“MI:0915”(physical association)	0.560
AKAP9	RSRC2	psi-mi:“MI:0915”(physical association)	0.560
RSRC2	PFDN5	psi-mi:“MI:0915”(physical association)	0.560
SAMD4B	RSRC2	psi-mi:“MI:0915”(physical association)	0.560
RSRC2	NAV1	psi-mi:“MI:0915”(physical association)	0.560
POT1	TERF1	psi-mi:“MI:0914”(association)	0.530
SRPK2	RRP9	psi-mi:“MI:0914”(association)	0.530
RSRC2	SRPK1	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
RSRC2	NOS1	psi-mi:“MI:0407”(direct interaction)	0.440
RSRC2	MAGI2	psi-mi:“MI:0407”(direct interaction)	0.440
RSRC2	LIN7C	psi-mi:“MI:0407”(direct interaction)	0.440
RSRC2	NHERF4	psi-mi:“MI:0407”(direct interaction)	0.440
APBA3	RSRC2	psi-mi:“MI:0407”(direct interaction)	0.440
RSRC2	MPP2	psi-mi:“MI:0407”(direct interaction)	0.440
RSRC2	LNX1	psi-mi:“MI:0407”(direct interaction)	0.440
RSRC2	DLG3	psi-mi:“MI:0407”(direct interaction)	0.440
RSRC2	TIAM2	psi-mi:“MI:0407”(direct interaction)	0.440
RSRC2	HTRA4	psi-mi:“MI:0407”(direct interaction)	0.440
RSRC2	LIN7B	psi-mi:“MI:0407”(direct interaction)	0.440
RSRC2	MAST2	psi-mi:“MI:0407”(direct interaction)	0.440
SNTB1	RSRC2	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (85): RSRC2 (Two-hybrid), RSRC2 (Two-hybrid), RSRC2 (Two-hybrid), RSRC2 (Two-hybrid), RSRC2 (Two-hybrid), RSRC2 (Two-hybrid), CMTM5 (Two-hybrid), CCDC155 (Two-hybrid), RSRC2 (Affinity Capture-RNA), RSRC2 (Affinity Capture-MS), RSRC2 (Proximity Label-MS), RSRC2 (Affinity Capture-MS), RSRC2 (Affinity Capture-MS), RSRC2 (Affinity Capture-MS), RSRC2 (Affinity Capture-MS)

ESM2 similar proteins: A0A1S3XQD6, A0A1S4AX27, A1A5I1, A2AR02, A6QLS2, B0BN49, G2TRQ9, O14256, O55035, P30189, P30414, P41512, Q04750, Q07050, Q13427, Q27450, Q28EE8, Q3KPW4, Q4V9W2, Q505I5, Q59LQ5, Q5BKY9, Q5R8J6, Q5RJP9, Q5VTL8, Q5XHJ5, Q5ZLM8, Q6AXY7, Q6BNE1, Q6NQD9, Q6NWI1, Q6ZUT1, Q751P0, Q7L4I2, Q7YR26, Q80SY5, Q8GWY0, Q8N9E0, Q8N9Q2, Q8R0F5

Diamond homologs: A2RTL5, A6QLS2, Q5PQR4, Q5R8J6, Q5XHJ5, Q6NWI1, Q7L4I2, Q7ZYR8

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 160 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Ras activation upon Ca2+ influx through NMDA receptor	5	26.9×	9e-05
Unblocking of NMDA receptors, glutamate binding and activation	5	25.6×	9e-05
Negative regulation of NMDA receptor-mediated neuronal transmission	5	25.6×	9e-05
Assembly and cell surface presentation of NMDA receptors	10	23.9×	2e-09
Dopamine Neurotransmitter Release Cycle	5	23.4×	1e-04
Long-term potentiation	5	22.4×	1e-04
Neurexins and neuroligins	11	20.4×	2e-09
Protein-protein interactions at synapses	7	17.5×	2e-05

GO biological processes:

GO term	Partners	Fold	FDR
establishment or maintenance of epithelial cell apical/basal polarity	10	39.0×	3e-11
protein localization to synapse	6	30.9×	7e-06
receptor clustering	7	29.3×	1e-06
negative regulation of mRNA splicing, via spliceosome	5	25.7×	1e-04
regulation of postsynaptic membrane neurotransmitter receptor levels	6	20.0×	5e-05
RNA polymerase II preinitiation complex assembly	5	9.1×	1e-02
cell-cell adhesion	11	7.5×	5e-05
protein-containing complex assembly	8	6.1×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

58 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	37
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
242899	NM_023012.6(RSRC2):c.425G>A (p.Arg142Gln)	Likely pathogenic

SpliceAI

1940 predictions. Top by Δscore:

Variant	Effect	Δscore
12:122505703:CACT:C	acceptor_gain	1.0000
12:122505705:CT:C	acceptor_gain	1.0000
12:122505706:TC:T	acceptor_loss	1.0000
12:122505707:C:A	acceptor_loss	1.0000
12:122505707:C:CC	acceptor_gain	1.0000
12:122505707:C:G	acceptor_gain	1.0000
12:122508213:CTTA:C	donor_loss	1.0000
12:122508214:TTA:T	donor_loss	1.0000
12:122508215:TA:T	donor_loss	1.0000
12:122508216:A:AC	donor_gain	1.0000
12:122508216:AC:A	donor_gain	1.0000
12:122508216:ACC:A	donor_gain	1.0000
12:122508216:ACCC:A	donor_gain	1.0000
12:122508217:C:CC	donor_gain	1.0000
12:122508217:CC:C	donor_gain	1.0000
12:122508217:CCC:C	donor_gain	1.0000
12:122508217:CCCC:C	donor_gain	1.0000
12:122508217:CCCCT:C	donor_gain	1.0000
12:122508448:CTG:C	acceptor_gain	1.0000
12:122508451:C:CC	acceptor_gain	1.0000
12:122508452:T:C	acceptor_gain	1.0000
12:122508452:T:TC	acceptor_gain	1.0000
12:122511186:AACCT:A	acceptor_loss	1.0000
12:122515120:T:TA	donor_gain	1.0000
12:122515226:CT:C	acceptor_gain	1.0000
12:122515228:C:CC	acceptor_gain	1.0000
12:122517221:ACCT:A	donor_loss	1.0000
12:122517222:CCTA:C	donor_loss	1.0000
12:122517223:CTAC:C	donor_loss	1.0000
12:122517225:A:AC	donor_gain	1.0000

AlphaMissense

2831 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:122505560:G:C	F424L	1.000
12:122505560:G:T	F424L	1.000
12:122505561:A:G	F424S	1.000
12:122505562:A:G	F424L	1.000
12:122505564:C:T	G423D	1.000
12:122505565:C:A	G423C	1.000
12:122505565:C:G	G423R	1.000
12:122505567:A:G	L422S	1.000
12:122505570:C:T	G421D	1.000
12:122505571:C:A	G421C	1.000
12:122505571:C:G	G421R	1.000
12:122505576:C:T	G419E	1.000
12:122505577:C:G	G419R	1.000
12:122505577:C:T	G419R	1.000
12:122505578:T:A	R418S	1.000
12:122505578:T:G	R418S	1.000
12:122505579:C:A	R418I	1.000
12:122505579:C:G	R418T	1.000
12:122505587:G:C	H415Q	1.000
12:122505587:G:T	H415Q	1.000
12:122505588:T:C	H415R	1.000
12:122505588:T:G	H415P	1.000
12:122505589:G:C	H415D	1.000
12:122505589:G:T	H415N	1.000
12:122505591:G:A	T414I	1.000
12:122505594:T:G	Q413P	1.000
12:122505598:A:G	S412P	1.000
12:122505599:T:A	R411S	1.000
12:122505599:T:G	R411S	1.000
12:122505600:C:A	R411I	1.000

dbSNP variants (sampled 300 via entrez): RS1000079184 (12:122523376 A>G,T), RS1000098248 (12:122514656 G>A,T), RS1000234036 (12:122504318 G>A,T), RS1000260379 (12:122504177 C>G), RS1000267637 (12:122528040 CAT>C), RS1000327871 (12:122504561 G>A,T), RS1000513300 (12:122508909 T>A), RS1000599295 (12:122505273 T>C), RS1001008639 (12:122527046 A>G), RS1001240146 (12:122508513 T>C), RS1001265984 (12:122503113 A>C,G), RS1001403463 (12:122505712 A>T), RS1001428720 (12:122519750 C>A,G), RS1001530596 (12:122522667 C>G), RS1001670479 (12:122515004 G>A,C)

Disease associations

OMIM: gene MIM:619996 | disease phenotypes: MIM:160700

GenCC curated gene-disease

Disease	Classification	Inheritance
complex neurodevelopmental disorder	Limited	Autosomal dominant

Mondo (4): myopia (MONDO:0001384), strabismus (MONDO:0003432), obesity disorder (MONDO:0011122), complex neurodevelopmental disorder (MONDO:0100038)

Orphanet (2): Obesity due to melanocortin 4 receptor deficiency (Orphanet:71529), NON RARE IN EUROPE: Non rare obesity (Orphanet:521399)

HPO phenotypes

2 total (2 of 2 shown, HPO-id order):

HPO	Term
HP:0000545	Myopia
HP:0001513	Obesity

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST90020025_123	Waist-to-hip ratio adjusted for BMI	4.000000e-08
GCST90020028_1245	Hip circumference adjusted for BMI	5.000000e-10

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008039	BMI-adjusted hip circumference

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D009216	Myopia	C11.744.636
D013285	Strabismus	C10.292.562.887; C11.590.810

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

69 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cadmium Chloride	affects expression, decreases expression, decreases methylation, increases expression	4
Cisplatin	decreases expression, affects cotreatment	2
Tobacco Smoke Pollution	increases expression	2
Valproic Acid	decreases expression, decreases methylation	2
Cyclosporine	increases expression	2
Aflatoxin B1	decreases methylation	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
FR900359	affects phosphorylation	1
bisphenol F	affects cotreatment, increases expression	1
graphene oxide	decreases expression	1
dicrotophos	decreases expression	1
chloroacetaldehyde	decreases expression	1
methylmercuric chloride	increases expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
bisphenol A	decreases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
beta-lapachone	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	increases expression	1
potassium chromate(VI)	affects cotreatment, increases expression	1
ferrous chloride	increases expression	1
methacrylaldehyde	affects cotreatment, decreases expression, increases abundance	1
epigallocatechin gallate	increases expression, affects cotreatment	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
pentabromodiphenyl ether	increases expression	1
chloropicrin	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
14-deoxy-11,12-didehydroandrographolide	increases expression	1
abrine	increases expression	1

Clinical trials (associated diseases)

302 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00347204	PHASE4	COMPLETED	Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK
NCT00349843	PHASE4	COMPLETED	Investigation of Multi-Purpose Solution-Based Corneal Staining and Ocular Comfort
NCT00349882	PHASE4	COMPLETED	Effects of Contact Lens Care Regimens on the Corneal Epithelium
NCT00350246	PHASE4	COMPLETED	Long-term Effects of Laser Refractive Surgery
NCT00404105	PHASE4	COMPLETED	A Comparison of PRK and LASIK for Correction of Myopia
NCT00455455	PHASE4	COMPLETED	Corneal and Conjunctival Sensitivity and Staining Study
NCT00541177	PHASE4	UNKNOWN	Study of Myopia Prevention in Children With Low Concentration of Atropine
NCT00627302	PHASE4	COMPLETED	Efficacy of PEG-400 and Systane Artificial Tears (Alcon) on Quality of Vision
NCT00640341	PHASE4	COMPLETED	Comparative Performance of PureVision, Acuvue Oasys and O2Optix
NCT00770094	PHASE4	UNKNOWN	Multi Laser Platform Comparison Study for LASIK
NCT00821236	PHASE4	COMPLETED	Contralateral Comparison of Three Excimer Laser Systems in Performing LASIK
NCT00889941	PHASE4	COMPLETED	Effect of Preoperative Pupil Size on Quality of Vision After Wavefront-Guided LASIK
NCT00937105	PHASE4	COMPLETED	Daily Wear Corneal Infiltrative Event Study
NCT01173198	PHASE4	COMPLETED	An Evaluation of Outcomes Following Wavefront Optimized or Wavefront Guided Lasik Procedure in Low to Moderate Myopic Patients
NCT01250925	PHASE4	COMPLETED	Effect of Contact Lens Wear on Immune Cell Density and Morphology of the Ocular Surface
NCT01387360	PHASE4	COMPLETED	Presbyopic Supracor Treatment for Near Myopic/Hyperopic Pseudophakic Eyes
NCT01454843	PHASE4	COMPLETED	LASIK Using the Alcon Allegretto Wavefront-Guided Excimer Laser vs AMO Visx Wavefront-Guided Excimer Laser
NCT01693939	PHASE4	COMPLETED	Evaluation of the Post-LASIK Flap Thickness of the FS200 Femtosecond Laser Flap
NCT01706237	PHASE4	WITHDRAWN	Visual Outcomes And Contrast Sensitivity After Myopic Wavefront-Optimized Lasik With Nexisvision Shield Or Bandage Contact Lens
NCT01746589	PHASE4	COMPLETED	Visual Outcomes and Contrast Sensitivity After Myopic LASIK
NCT01977807	PHASE4	UNKNOWN	A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser in Asian Eyes Using LASIK
NCT02071576	PHASE4	UNKNOWN	A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser Using LASIK
NCT02112968	PHASE4	UNKNOWN	A Prospective Safety and Effectiveness Study of a New High Repetition Rate Excimer Laser Using LASIK for the Correction of Ammetropia and Presbyopia
NCT02186184	PHASE4	COMPLETED	Effect of Orthokeratology Versus Spectacles on Myopia Progression in Chinese Children: A Crossover Trial
NCT02544529	PHASE4	WITHDRAWN	Echothiophate Iodide for the Prevention of Progression of Myopia
NCT03001401	PHASE4	UNKNOWN	Comparison of Next Generation Laser Techniques of Myopia Correction: iDesign vs. SMILE
NCT03158142	PHASE4	COMPLETED	The Influence of Atropine on Choroidal Thickness
NCT03544827	PHASE4	COMPLETED	The Effects of Low Dose Atropine on Choroidal Thickness
NCT03881670	PHASE4	COMPLETED	On-Eye Optical Quality of Lotrafilcon B Lenses Over 12 Hours
NCT03949101	PHASE4	UNKNOWN	Atropine for Children and Adolescent Myopia Progression Study
NCT04208750	PHASE4	COMPLETED	Clinical Investigation of the Vision-R800 Device.
NCT04283331	PHASE4	UNKNOWN	Anesthetic Impregnated Bandage Soft Contact Lens (BSCL) in Pain Management After Photorefractive Keratectomy (PRK)
NCT05357326	PHASE4	UNKNOWN	Myopia Intervention in Children and Adolescents and Establishment of a Precise Intervention Model
NCT05448989	PHASE4	UNKNOWN	Efficacy and Safety of 1% Atropine 5+3 Regimen in Children and Adolescents Controlling Myopia
NCT05449015	PHASE4	UNKNOWN	Study on the Effect of Two Ways of Cycloplegia on Biological Parameters of Ciliary Muscle
NCT05733741	PHASE4	COMPLETED	Preservative-free Topical Anesthetics for Post-PRK Pain
NCT05803863	PHASE4	UNKNOWN	Efficacy Comparison of 2 Low-dose Atropine Eye Drops in Vietnamese Children Myopia Management
NCT06431841	PHASE4	ACTIVE_NOT_RECRUITING	Atropine and Spectacle Combination Treatment (ASPECT): 12-month Results of a Randomized Clinical Trial for Myopia Control
NCT06450132	PHASE4	ACTIVE_NOT_RECRUITING	Changes in Eye Shape With Myopia Management Interventions
NCT06553404	PHASE4	ACTIVE_NOT_RECRUITING	Myoslow Lens Study to Control Myopia in Children